Avicanna Inc. (AVCNF) Stock

About Avicanna Inc.

Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors. It maintains partnerships with Canadian academic and medical institutions. Its scientific approach, encompassing robust R&D and clinical development, underpins the commercialization of roughly twenty products across four primary market segments. The company offers a diverse portfolio, including: RHO Phyto: Medical and wellness products containing cannabinoids such as CBD, CBG, and THC. Pura H&W and Pura Earth: Functional CBD-infused derma-cosmetic and topical products for consumers. Aureus: A range of cannabis and hemp-derived goods, including dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations. Furthermore, Avicanna is developing pharmaceutical solutions targeting conditions such as epidermolysis bullosa, dermatological issues, chronic pain, and various neurological disorders. A notable research collaboration exists with Dr. Christine Allen's Research Group, investigating cannabinoid-based treatments for lung inflammation associated with COVID-19. Incorporated in 2016, Avicanna Inc. is headquartered in Toronto, Canada.

Avicanna Inc. is headquartered in CA.

Avicanna Inc. (AVCNF) stock trades at $0.10 with a market capitalization of $12.15M. The stock is valued at a price-to-earnings (P/E) ratio of -4.25, price-to-book of 4.00, price-to-sales of 0.63. Over the past 52 weeks the stock has ranged between $0.07 and $0.24, and currently trades 58.3% below its 52-week high.

On profitability, Avicanna Inc. generates a return on equity (ROE) of -116.09%, return on capital employed of -25.02%, an operating margin of -12.95%, a net profit margin of -13.90%.

Official website: www.avicanna.com